GLP-1 and reduced risk of renal failure in patients with bipolar disorder

A recent study published in the Journal of Clinical Psychiatry investigated the association between the use of GLP-1 receptor agonists and the risk of renal replacement therapy in adults with bipolar disorder and chronic kidney disease. The researchers used de-identified electronic health data from the TriNetX network, which includes records of approximately 131 million adults in 117 healthcare systems around the world. The research focused on adults with bipolar disorder and mild to moderate chronic kidney disease who started using GLP-1 medications or comparative treatments ^1,2.

Methodology and Results

The researchers compared patients using GLP-1 receptor agonists with those taking DPP-4 inhibitors or renin-angiotensin-aldosterone system (RAAS) inhibitors. They used statistical matching techniques to make the groups more comparable and followed the outcomes for up to five years. The results indicated that the use of GLP-1 receptor agonists was associated with a lower risk of renal replacement therapy and healthcare service utilization compared to the other treatments ¹.

Benefits and Limitations

The observed benefits were consistent across different subgroups, including sex, race, obesity status, and use of psychotropic medications. However, the authors highlight that the findings are exploratory and require further investigations, including prospective studies, to assess whether the association reflects a causal effect ¹.

Chronic kidney disease is a significant concern in patients with bipolar disorder due to high rates of obesity, diabetes, and hypertension, as well as the potential renal effects of some psychiatric medications. GLP-1 receptor agonists, initially developed to treat type 2 diabetes, are also used for weight management and have shown benefits for renal and cardiac health in people with diabetes and chronic kidney disease ².